Who is the CEO of OmniAb, Inc.?

Mr. Matthew W. Foehr is a business executive who currently serves as the CEO of OmniAb, Inc..

What is the Revenue Growth of OmniAb, Inc.?

Revenue growth data for OmniAb, Inc. is currently unavailable.

What is OmniAb, Inc. operating Margin?

OmniAb, Inc. operating margin is -264.71% which shows how much profit OABIW earns from each dollar of sales, after subtracting the direct costs tied to generating that revenue.

In which market sector does OmniAb, Inc. operate?

OmniAb, Inc. falls under the Healthcare sector which thrives across multiple industries. It stays competitive through its diverse product lineup, which spans computer hardware, tech gadgets, video streaming services, and cloud computing solutions.

What is OmniAb, Inc. revenue growth?

Revenue growth data for OmniAb, Inc. is currently unavailable.

What is the IPO date for OmniAb, Inc. stock?

IPO date for OmniAb, Inc. is currently unavailable.

OmniAb, Inc.

OABIW•NASDAQ

Healthcare

Biotechnology

$0.24

$0.03(13.56%)

OmniAb, Inc. (OABIW) Stock Overview

Explore OmniAb, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for OABIWStats details for OABIW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Analyst Recommendations data is not available for OABIWAnalyst Recommendations details for OABIW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.

CEO

Mr. Matthew W. Foehr

Employees

114

Headquarters

5980 Horton Street, EmeryVille, CA

Founded

1970